Previous close | 964.40 |
Open | 965.00 |
Bid | 980.60 x 0 |
Ask | 980.80 x 0 |
Day's range | 965.00 - 982.40 |
52-week range | 887.00 - 1,316.75 |
Volume | |
Avg. volume | 3,622,896 |
Market cap | 8.575B |
Beta (5Y monthly) | 0.51 |
PE ratio (TTM) | 40.87 |
EPS (TTM) | 0.24 |
Earnings date | 27 Feb 2024 |
Forward dividend & yield | 0.30 (3.14%) |
Ex-dividend date | 28 Mar 2024 |
1y target est | 12.87 |
Key Insights Given the large stake in the stock by institutions, Smith & Nephew's stock price might be vulnerable to...
Smith+Nephew (NYSE:SNN; LSE:SN), the global medical technology company is pleased to announce exciting data for its ALLEVYN LIFE Dressing in a recent study by Professor Amit Gefen and his research group published in the International Wound Journal,1 that shows a novel mechanism of action relating to pressure injury prevention (PIP). The study found that due to the independent and non-bonded internal layers of ALLEVYN LIFE Dressing, a layer-on-layer sliding phenomenon occurs and allows for dissip
This powerhouse FTSE stock has embarked on a new growth strategy that’s already showing good results, but it looks undervalued to me. The post Down 27%, but set for major growth, this hidden FTSE gem looks cheap to me appeared first on The Motley Fool UK.